SCRS, Lilly Announces Site Engagement Partnership
Ellicott City, MD – SCRS and Eli Lilly & Company today announced a Site Engagement Partnership, which allows for significant involvement and increasing direct communication with the sites. Through this partnership, Lilly brings their commitment to excellence to site development and site sustainability. “SCRS welcomes this significant partnership with Lilly, who has been a strong Global Impact Partner since 2013,” said Christine Pierre, President of SCRS. “Lilly is taking a significant leadership role in bolstering its commitment to site sustainability and continuing to connect site members with patient-centered movements in clinical research.” “Lilly greatly values our partnership with SCRS as we work together to enhance the strengths and address the challenges of conducting clinical research, particularly through the close collaborations with investigative sites. We are excited to increase our areas of SCRS global participation, further indicating our commitment to incorporating site feedback and being involved in development of solutions to achieve the mutual goal of bringing new medicines to patients,” stated Meri Kay Scott, Senior Director, Global Clinical Operations, Eli Lilly and Company. About SCRS SCRS is a global trade organization founded in 2012 which represents over 4,000 research sites in 54 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Visit
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025